|Bid||0.00 x 10000|
|Ask||0.00 x 10000|
|Day's Range||237.40 - 238.70|
|52 Week Range||161.00 - 261.80|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||9.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BURLINGTON, N.C., October 01, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with
BURLINGTON, N.C., September 28, 2021--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2021 before the market opens on Thursday, October 28, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.
BURLINGTON, N.C., September 13, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay.